Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.

BMC research notes - 8 Apr 2013

Umekawa Kanako, Kimura Tatsuo, Kudoh Shinzoh, Suzumura Tomohiro, Oka Takako, Nagata Misato, Mitsuoka Shigeki, Matsuura Kuniomi, Nakai Toshiyuki, Yoshimura Naruo, Kira Yukimi, Hirata Kazuto

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent response and improved performance status. Recently, pro-inflammatory cytokines, such as regulated upon activation normal T cell expressed and secreted (RANTES), interleukin (IL)-10 and IL-8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Quinazolines
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chemokine CCL5

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Inflammation

Share to Interleukin-10

Share to Interleukin-8

Source

Open in PubMed Open full text

Identifiers

PMID: 23566546
DOI: 10.1186/1756-0500-6-139
PMCID: PMC3637543

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.PMID 23566546Read ↗

Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopulations in Patients Treated for Lung AdenocarcinomaSemantic proximity Read ↗

Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.Semantic proximity Read ↗

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.Semantic proximity Read ↗

Prognostic value of the neutrophil-to-lymphocyte ratio and primary tumor location in patients with EGFR-mutated metastatic non-small cell lung cancer treated with TKIsNote: We found that we got a wrong results in the previous article. So, we checked our collected database and calculated again and corrected now.Semantic proximity Read ↗

The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.Semantic proximity Read ↗

Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.Semantic proximity Read ↗

Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.